Longevity and cardiovascular health 2025

Vascular ageing is not a purely “biological” concept, but can be measured clinically – via arterial stiffness (e.g. PWV), endothelial function (e.g. FMD) and the resulting risk profiles. In parallel to established prevention (blood pressure, lipids, smoking, exercise), two dynamic development strands are emerging: increasingly potent and longer-acting lipid-lowering drugs through to Lp(a) targeting (outcomes partly still pending), and geroprotective signaling pathway interventions (mTOR modulation), for which relevant human pilot data on endothelial function were also published in 2024/2025.